Agents that induce the expression of GCNT3 might be potential antitumor drugs for CRC and EOC, with the aim of reducing adverse events and overcoming drug resistance that is a current and necessary demand for patients and health systems. The gene discussed is GCNT3; the disease is colorectal carcinoma.